Clinical Trials Browser

Phase 1/2 × Leukemia × enasidenib × Clear all

NCT05282459 2025-03-20

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Phase 1/2 Completed

Other hematologic neoplasm

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid